MBX Biosciences (MBX) Financials

MBX Biosciences logo
$53.12 -2.82 (-5.04%)
Closing price 04:00 PM Eastern
Extended Trading
$53.12 0.00 (0.00%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for MBX Biosciences

Annual Income Statements for MBX Biosciences

This table shows MBX Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-33 -62 -87
Consolidated Net Income / (Loss)
-33 -62 -87
Net Income / (Loss) Continuing Operations
-33 -62 -87
Total Pre-Tax Income
-33 -62 -87
Total Operating Income
-35 -68 -98
Total Gross Profit
0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
35 68 98
Selling, General & Admin Expense
6.78 11 19
Research & Development Expense
29 57 79
Total Other Income / (Expense), net
2.75 6.27 11
Interest & Investment Income
2.75 6.27 11
Basic Earnings per Share
($31.96) ($5.82) ($2.38)
Weighted Average Basic Shares Outstanding
1.02M 10.64M 36.51M
Diluted Earnings per Share
($31.96) ($5.82) ($2.38)
Weighted Average Diluted Shares Outstanding
1.02M 10.64M 36.51M
Weighted Average Basic & Diluted Shares Outstanding
- 33.42M 47.51M

Quarterly Income Statements for MBX Biosciences

This table shows MBX Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Consolidated Net Income / (Loss)
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Net Income / (Loss) Continuing Operations
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Total Pre-Tax Income
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Total Operating Income
-13 -17 -20 -19 -27 -22 -24 -26 -27 -41 -66
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
13 17 20 19 27 22 24 26 27 41 66
Selling, General & Admin Expense
2.27 2.26 2.87 3.39 4.12 4.08 4.66 6.04 8.79 9.95 34
Research & Development Expense
11 14 17 15 22 18 19 20 18 31 32
Total Other Income / (Expense), net
0.98 0.80 1.47 3.02 2.65 2.39 2.31 3.73 3.75 3.84 3.92
Interest & Investment Income
0.98 0.80 1.47 3.02 2.65 2.39 2.31 3.73 3.75 3.84 3.92
Basic Earnings per Share
($10.26) ($12.62) ($2.78) $19.84 ($0.71) ($0.58) ($0.63) ($0.46) ($0.50) ($0.78) ($1.29)
Weighted Average Basic Shares Outstanding
1.20M 1.26M 6.52M 10.64M 33.41M 33.45M 34.20M 36.51M 46.58M 47.70M 48.56M
Diluted Earnings per Share
($10.26) ($12.62) ($2.78) $19.84 ($0.71) ($0.58) ($0.63) ($0.46) ($0.50) ($0.78) ($1.29)
Weighted Average Diluted Shares Outstanding
1.20M 1.26M 6.52M 10.64M 33.41M 33.45M 34.20M 36.51M 46.58M 47.70M 48.56M
Weighted Average Basic & Diluted Shares Outstanding
- - 33.42M 33.42M 33.42M 33.59M 44.90M 47.51M 47.60M 48.16M 49.66M

Annual Cash Flow Statements for MBX Biosciences

This table details how cash moves in and out of MBX Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
6.31 19 26
Net Cash From Operating Activities
-32 -55 -80
Net Cash From Continuing Operating Activities
-32 -55 -80
Net Income / (Loss) Continuing Operations
-33 -62 -87
Consolidated Net Income / (Loss)
-33 -62 -87
Depreciation Expense
0.16 0.24 0.25
Amortization Expense
-1.04 -2.93 -3.61
Non-Cash Adjustments To Reconcile Net Income
2.21 5.18 8.73
Changes in Operating Assets and Liabilities, net
-0.74 4.75 1.65
Net Cash From Investing Activities
-31 -161 -84
Net Cash From Continuing Investing Activities
-31 -161 -84
Purchase of Property, Plant & Equipment
-0.13 -0.87 -1.93
Purchase of Investments
-64 -239 -358
Sale and/or Maturity of Investments
33 80 268
Other Investing Activities, net
- 0.00 8.50
Net Cash From Financing Activities
69 234 190
Net Cash From Continuing Financing Activities
69 234 190
Repurchase of Preferred Equity
-0.03 -0.28 0.00
Repurchase of Common Equity
0.00 -4.06 -0.77
Issuance of Debt
- 0.00 188
Issuance of Preferred Equity
69 64 0.00
Issuance of Common Equity
0.00 175 0.00
Other Financing Activities, net
0.74 0.40 2.42

Quarterly Cash Flow Statements for MBX Biosciences

This table details how cash moves in and out of MBX Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
4.90 -23 120 -84 -19 9.88 183 -148 -30 8.91 108
Net Cash From Operating Activities
-11 -13 -15 -16 -23 -17 -22 -18 -20 -23 -35
Net Cash From Continuing Operating Activities
-11 -13 -15 -16 -23 -17 -22 -18 -20 -23 -35
Net Income / (Loss) Continuing Operations
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Consolidated Net Income / (Loss)
-12 -16 -18 -16 -24 -19 -22 -22 -24 -37 -62
Depreciation Expense
0.05 0.06 0.08 0.06 0.08 0.06 0.05 0.06 0.06 0.08 0.14
Amortization Expense
-0.50 -0.44 -0.59 -1.40 -1.34 -0.98 -0.73 -0.56 -0.58 -0.42 -0.21
Non-Cash Adjustments To Reconcile Net Income
1.61 0.98 1.11 1.48 1.83 1.41 2.79 2.66 5.48 6.54 28
Changes in Operating Assets and Liabilities, net
0.47 1.98 2.88 -0.59 0.64 1.48 -2.03 1.60 -1.65 8.27 -0.04
Net Cash From Investing Activities
15 -7.89 -101 -67 3.23 26 17 -130 -97 29 43
Net Cash From Continuing Investing Activities
15 -7.89 -101 -67 3.23 26 17 -130 -97 29 43
Purchase of Property, Plant & Equipment
-0.27 -0.45 -0.06 -0.09 -0.03 -0.71 -0.40 -0.79 -0.44 -0.90 -1.19
Purchase of Investments
-8.55 -16 -128 -88 -59 -47 -46 -205 -154 -54 -30
Sale and/or Maturity of Investments
24 8.25 27 20 57 73 61 76 58 84 74
Net Cash From Financing Activities
0.18 -1.76 236 -0.13 0.00 1.33 188 0.44 87 2.32 100
Net Cash From Continuing Financing Activities
0.18 -1.76 236 -0.13 0.00 1.33 188 0.44 87 2.32 100
Repurchase of Common Equity
-0.01 -1.81 -1.92 -0.33 0.00 - -0.25 -0.52 -0.38 -0.13 -0.03
Issuance of Common Equity
0.00 - 175 - 0.00 - - - 85 0.25 97
Other Financing Activities, net
0.19 0.05 -0.03 0.20 0.00 1.33 0.13 0.96 2.44 2.19 2.41

Annual Balance Sheets for MBX Biosciences

This table presents MBX Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
Total Assets
84 269 385
Total Current Assets
83 267 382
Cash & Equivalents
31 49 75
Short-Term Investments
50 213 298
Prepaid Expenses
2.79 5.14 7.83
Plant, Property, & Equipment, net
0.44 1.08 2.74
Total Noncurrent Assets
0.28 0.17 0.87
Other Noncurrent Operating Assets
0.28 0.17 0.87
Total Liabilities & Shareholders' Equity
84 269 385
Total Liabilities
4.29 11 16
Total Current Liabilities
3.93 11 15
Accounts Payable
1.39 5.34 2.98
Accrued Expenses
2.38 5.55 12
Other Current Liabilities
0.15 0.17 0.17
Total Noncurrent Liabilities
0.37 0.04 0.43
Other Noncurrent Operating Liabilities
0.37 0.04 0.43
Commitments & Contingencies
0.00 0.00 0.00
Redeemable Noncontrolling Interest
152 0.00 0.00
Total Equity & Noncontrolling Interests
-72 257 369
Total Preferred & Common Equity
-72 257 369
Preferred Stock
0.00 0.00 0.00
Total Common Equity
-72 257 369
Common Stock
3.06 395 593
Retained Earnings
-76 -138 -224
Accumulated Other Comprehensive Income / (Loss)
0.06 0.06 0.29

Quarterly Balance Sheets for MBX Biosciences

This table presents MBX Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
282 246 232 400 453 436 501
Total Current Assets
281 244 229 398 449 428 493
Cash & Equivalents
133 30 40 223 45 54 162
Short-Term Investments
144 211 185 169 395 364 320
Prepaid Expenses
4.11 3.49 4.28 5.83 8.56 9.28 11
Plant, Property, & Equipment, net
1.03 1.51 1.73 2.00 3.13 4.66 5.00
Total Noncurrent Assets
0.20 0.14 0.60 0.57 1.03 3.38 2.86
Other Noncurrent Operating Assets
0.20 0.14 0.60 0.57 1.03 3.38 2.86
Total Liabilities & Shareholders' Equity
282 246 232 400 453 436 501
Total Liabilities
11 11 12 13 15 26 28
Total Current Liabilities
11 10 12 12 15 24 25
Accounts Payable
5.00 4.25 5.76 3.77 6.97 4.36 6.81
Accrued Expenses
5.75 6.11 5.85 8.14 7.42 19 18
Other Current Liabilities
0.17 0.13 0.14 0.15 0.18 0.63 0.79
Total Noncurrent Liabilities
0.11 0.02 0.53 0.48 0.38 2.71 2.50
Other Noncurrent Operating Liabilities
0.11 0.02 0.53 0.48 0.38 2.71 2.50
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
271 235 219 388 438 410 473
Total Preferred & Common Equity
271 235 219 388 438 410 473
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
271 235 219 388 438 410 473
Common Stock
393 397 400 590 686 696 822
Retained Earnings
-122 -161 -181 -202 -248 -285 -348
Accumulated Other Comprehensive Income / (Loss)
0.11 0.05 0.01 0.15 -0.61 -1.22 -1.96

Annual Metrics And Ratios for MBX Biosciences

This table displays calculated financial ratios and metrics derived from MBX Biosciences' official financial filings.

Metric 2023 2024 2025
Period end date 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 - 44,902,302.00
DEI Adjusted Shares Outstanding
0.00 - 44,902,302.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 - -1.94
Growth Metrics
- - -
Profitability Metrics
- - -
Net Operating Profit after Tax (NOPAT)
-25 -48 -69
Return On Investment Capital (ROIC_SIMPLE)
34.11% -18.54% -18.59%
Earnings before Interest and Taxes (EBIT)
-35 -68 -98
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-36 -71 -101
Valuation Ratios
- - -
Leverage & Solvency
- - -
Liquidity Ratios
- - -
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
0.00 -44 -69
Efficiency Ratios
- - -
Capital & Investment Metrics
- - -
Invested Capital
-0.79 -4.71 -4.48
Increase / (Decrease) in Invested Capital
0.00 -3.92 0.23
Book Value per Share
($71.13) $7.70 $8.22
Tangible Book Value per Share
($71.13) $7.70 $8.22
Total Capital
80 257 369
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-81 -262 -374
Capital Expenditures (CapEx)
0.13 0.87 1.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.14 -5.91 -7.66
Debt-free Net Working Capital (DFNWC)
80 256 366
Net Working Capital (NWC)
80 256 366
Net Nonoperating Expense (NNE)
7.85 14 18
Net Nonoperating Obligations (NNO)
-81 -262 -374
Total Depreciation and Amortization (D&A)
-0.89 -2.68 -3.36
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 ($5.82) ($2.38)
Adjusted Weighted Average Basic Shares Outstanding
0.00 10.64M 36.51M
Adjusted Diluted Earnings per Share
$0.00 ($5.82) ($2.38)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 10.64M 36.51M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 33.42M 47.51M
Normalized Net Operating Profit after Tax (NOPAT)
-25 -48 -69
Debt Service Ratios
- - -
Payout Ratios
- - -

Quarterly Metrics And Ratios for MBX Biosciences

This table displays calculated financial ratios and metrics derived from MBX Biosciences' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
0.00 0.00 0.00 33,417,418.00 33,424,371.00 33,424,371.00 33,593,866.00 44,902,302.00 47,510,243.00 47,597,536.00 48,160,096.00
DEI Adjusted Shares Outstanding
0.00 0.00 0.00 33,417,418.00 33,424,371.00 33,424,371.00 33,593,866.00 44,902,302.00 47,510,243.00 47,597,536.00 48,160,096.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 0.00 -0.47 -0.71 -0.58 -0.64 -0.49 -0.50 -0.78 -1.30
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Growth
0.00% 0.00% -83.86% - -101.87% -33.38% -22.29% - 0.05% -81.64% -169.85%
EBIT Growth
0.00% 0.00% -79.19% - -99.26% -30.90% -22.00% - -2.77% -87.71% -177.28%
NOPAT Growth
0.00% 0.00% -79.19% - -99.26% -30.90% -22.00% - -2.77% -87.71% -177.28%
Net Income Growth
0.00% 0.00% -78.53% - -93.56% -22.41% -19.16% - 1.52% -91.10% -188.75%
EPS Growth
0.00% 0.00% 70.43% - 93.08% 95.40% 77.34% - 29.58% -34.48% -104.76%
Operating Cash Flow Growth
0.00% 0.00% 0.00% - -111.75% -31.38% -46.86% - 10.89% -29.76% -61.95%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% - 0.00% 0.00% -127.90% - -68.32% -163.43% -129.01%
Invested Capital Growth
0.00% 0.00% 0.00% - 0.00% 0.00% 27.39% - 58.59% -59.53% -109.12%
Revenue Q/Q Growth
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -23.73% -18.13% - 0.00% 18.25% -8.30% - -5.67% -48.57% -60.90%
EBIT Q/Q Growth
0.00% -25.12% -17.73% - 0.00% 17.81% -9.73% - -5.70% -50.12% -62.09%
NOPAT Q/Q Growth
0.00% -25.12% -17.73% - 0.00% 17.81% -9.73% - -5.70% -50.12% -62.09%
Net Income Q/Q Growth
0.00% -28.53% -14.41% - 0.00% 18.71% -11.37% - -6.60% -57.74% -68.27%
EPS Q/Q Growth
0.00% -23.00% 77.97% - 0.00% 18.31% -8.62% - -8.70% -56.00% -65.38%
Operating Cash Flow Q/Q Growth
3.91% -23.90% -10.50% - -41.41% 23.12% -23.53% - -10.42% -11.95% -54.17%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% - 0.00% 27.34% -90.80% - -21.59% -13.72% -65.87%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% - 0.00% -5.67% 27.05% - 50.45% -307.11% 4.37%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% - 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Interest Burden Percent
92.66% 95.19% 92.50% - 90.01% 89.02% 90.35% - 86.25% 90.63% 94.09%
Effective Tax Rate
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
0.00% 0.00% 0.00% - -31.21% -35.13% -24.43% - -25.73% -33.17% -33.72%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% - -31.21% -35.13% -24.43% - -25.73% -33.17% -33.72%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% - -31.21% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.32 -12 -14 -13 -19 -15 -17 -18 -19 -29 -46
NOPAT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
0.00% 0.00% -3.19% - -4.41% -3.69% -1.46% - -1.30% -2.62% -3.66%
Return On Investment Capital (ROIC_SIMPLE)
- - -5.06% -5.06% -7.89% -6.96% -4.32% -4.89% -4.36% -7.00% -9.82%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-13 -17 -20 -19 -27 -22 -24 -26 -27 -41 -66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-14 -17 -20 -20 -28 -23 -25 -26 -28 -41 -66
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.62 - 1.05 1.74 1.54 - 3.18 6.43 6.02
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.62 - 1.05 1.74 1.54 - 3.18 6.43 6.02
Price to Revenue (P/Rev)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
0.00 0.00 -1.02 - -1.02 -1.03 -1.01 - -1.01 -1.02 -1.01
Leverage Ratio
0.00 0.00 1.04 - 1.04 1.06 1.04 - 1.04 1.06 1.05
Compound Leverage Factor
0.00 0.00 0.96 - 0.94 0.94 0.94 - 0.90 0.96 0.98
Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 0.00% 100.00% - 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
0.00 0.00 0.00 - 13.95 18.36 28.89 - 56.00 59.79 61.43
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.00 0.00 25.75 - 23.31 19.50 32.95 - 30.79 18.08 19.58
Quick Ratio
0.00 0.00 25.37 - 22.97 19.13 32.47 - 30.20 17.69 19.14
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 -8.03 0.00 -13 -9.60 -18 -18 -22 -25 -42
Operating Cash Flow to CapEx
-3,923.08% -2,935.84% -25,726.32% - -75,593.33% -2,465.91% -5,397.49% - -4,624.26% -2,510.77% -2,928.38%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.00 0.00 -5.70 -4.71 -5.36 -5.67 -4.14 -4.48 -2.22 -9.04 -8.65
Invested Capital Turnover
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
0.00 0.00 -5.70 0.00 -5.36 -5.67 1.56 0.23 3.14 -3.37 -4.51
Enterprise Value (EV)
0.00 0.00 -108 - 5.80 157 207 - 950 2,214 2,365
Market Capitalization
163 163 169 - 247 382 598 - 1,390 2,633 2,847
Book Value per Share
$0.00 $0.00 $41.65 $7.70 $7.04 $6.56 $11.54 $8.22 $9.21 $8.60 $9.82
Tangible Book Value per Share
$0.00 $0.00 $41.65 $7.70 $7.04 $6.56 $11.54 $8.22 $9.21 $8.60 $9.82
Total Capital
0.00 0.00 271 257 235 219 388 369 438 410 473
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 0.00 -277 -262 -241 -225 -392 -374 -440 -419 -482
Capital Expenditures (CapEx)
0.27 0.45 0.06 0.09 0.03 0.71 0.40 0.79 0.44 0.90 1.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 0.00 -6.81 -5.91 -6.99 -7.47 -6.23 -7.66 -6.01 -14 -14
Debt-free Net Working Capital (DFNWC)
0.00 0.00 270 256 234 217 385 366 434 404 468
Net Working Capital (NWC)
0.00 0.00 270 256 234 217 385 366 434 404 468
Net Nonoperating Expense (NNE)
3.02 4.20 4.41 2.56 5.31 4.15 4.87 4.01 4.43 8.44 16
Net Nonoperating Obligations (NNO)
0.00 0.00 -277 -262 -241 -225 -392 -374 -440 -419 -482
Total Depreciation and Amortization (D&A)
-0.46 -0.38 -0.51 -1.34 -1.27 -0.92 -0.68 -0.50 -0.52 -0.34 -0.07
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($2.78) $19.84 ($0.71) ($0.58) ($0.63) ($0.46) ($0.50) ($0.78) ($1.29)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 6.52M 10.64M 33.41M 33.45M 34.20M 36.51M 46.58M 47.70M 48.56M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($2.78) $19.84 ($0.71) ($0.58) ($0.63) ($0.46) ($0.50) ($0.78) ($1.29)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 6.52M 10.64M 33.41M 33.45M 34.20M 36.51M 46.58M 47.70M 48.56M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 33.42M 33.42M 33.42M 33.59M 44.90M 47.51M 47.60M 48.16M 49.66M
Normalized Net Operating Profit after Tax (NOPAT)
-9.32 -12 -14 -13 -19 -15 -17 -18 -19 -29 -46
Normalized NOPAT Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% - 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% - -5.52% -2.91% -0.72% - -1.33% -1.22% -0.73%

Financials Breakdown Chart

Key Financial Trends

MBX Biosciences remains a development-stage biotechnology company with no reported revenue across the periods provided. Its financial profile is characterized by increasing research spending, persistent operating losses and substantial reliance on cash reserves and equity financing.

The balance sheet remains relatively strong from a liquidity perspective. As of June 30, 2026, MBX had $54.1 million in cash and $364.5 million in short-term investments, or approximately $418.7 million in cash and liquid investments. Total liabilities were only $26.4 million against $435.9 million of assets. The company’s current ratio was approximately 18, indicating considerable capacity to meet near-term obligations.

However, liquidity has been supported in part by capital markets rather than operating activity. MBX raised approximately $85.4 million through common-equity issuance in the first quarter of 2026 and $174.5 million in the third quarter of 2025. These financings improved the cash position but increased the potential for shareholder dilution.

Operating performance continues to deteriorate as MBX advances its pipeline. Revenue was zero in every income statement period supplied, while quarterly operating expenses increased from $18.6 million in the fourth quarter of 2024 to $40.9 million in the second quarter of 2026. Research and development spending reached $31.0 million in the latest quarter, up sharply from $15.2 million in the fourth quarter of 2024.

Net losses have also widened. MBX reported a $37.1 million net loss, or $0.78 per diluted share, in the second quarter of 2026, compared with losses of $23.5 million in the first quarter of 2026 and $19.4 million in the restated second quarter of 2025. Interest and investment income of $3.8 million partially offset operating costs, but it was not enough to produce a profit.

  • Substantial liquidity: Cash and short-term investments totaled approximately $418.7 million at June 30, 2026, providing a meaningful financial cushion for clinical development.
  • Low balance-sheet leverage: Total liabilities of $26.4 million were modest relative to total assets of $435.9 million, and the data shows no material debt issuance.
  • Potential operating runway: If the latest quarterly operating cash burn of $22.6 million remained stable, existing cash and short-term investments could theoretically cover roughly 18 quarters. Actual runway could be shorter if clinical spending accelerates or investment balances are needed for other purposes.
  • Investment income provides support: Interest and investment income increased from $1.5 million in the third quarter of 2024 to $3.8 million in the second quarter of 2026, helping reduce—but not eliminate—the net loss.
  • Investment portfolio activity is significant: MBX regularly purchases and sells short-term investments. The second quarter of 2026 generated $29.2 million of investing cash flow, primarily because $84.0 million of investments matured or were sold, so the improvement in total cash flow does not represent operating profitability.
  • No commercial revenue has been reported: Revenue and gross profit were zero in each supplied income statement period, leaving MBX dependent on financing and investment income.
  • Operating losses are expanding: Quarterly operating expenses rose to $40.9 million in Q2 2026 from $26.5 million in Q1 2025 and $18.6 million in Q4 2024. The latest net loss of $37.1 million was the largest in the periods provided.
  • Operating cash flow remains consistently negative: Cash used in operations was $22.6 million in Q2 2026 and has generally remained between approximately $17 million and $23 million per quarter since 2025.
  • Shareholder dilution is a continuing risk: Common-equity issuance of $85.4 million in Q1 2026 and $174.5 million in Q3 2025 helped fund the business. Weighted-average basic shares increased to 47.7 million in Q2 2026 from 33.4 million in Q1 2025.
  • Accumulated losses are substantial: Retained earnings were negative $285.1 million at June 30, 2026, compared with negative $180.8 million at June 30, 2025, reflecting the company’s continuing pre-commercial investment phase.

Overall, MBX’s financial statements show a company with a strong near-term liquidity position but no internally generated revenue and a rapidly increasing cost base. For investors, the key issues are whether higher research spending produces favorable clinical and regulatory outcomes, how long the current capital supports development, and whether additional equity offerings will be required before commercialization.

11/16/26 11:07 PM ETAI Generated. May Contain Errors.

MBX Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MBX Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

MBX Biosciences' net income appears to be on a downward trend, with a most recent value of -$86.97 million in 2025, falling from -$32.56 million in 2023. The previous period was -$61.92 million in 2024. View MBX Biosciences' forecast to see where analysts expect MBX Biosciences to go next.

MBX Biosciences' total operating income in 2025 was -$98.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $98.06 million

Over the last 2 years, MBX Biosciences' total revenue changed from $0.00 in 2023 to $0.00 in 2025, a change of 0.0%.

In the past 8 quarters, MBX Biosciences' cash and equivalents has ranged from $29.90 million in Q1 2025 to $223.13 million in Q3 2025, and is currently $161.69 million as of their latest financial filing in Q3 2026.

MBX Biosciences had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2023.

Over the last 2 years, MBX Biosciences' book value per share changed from -71.13 in 2023 to 8.22 in 2025.



Financial statements for NASDAQ:MBX last updated on 11/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners